Emerging pathogens

Medical Mycology

Volumn 38, Issue , 2000, Pages 225-236

  Ponton J ^a   Ruchel R ^b   Clemons, K V ^c,h   Coleman, D C ^d   Grillot, R ^e   Guarro, J ^f   Aldebert, D ^e   Ambroise Thomas, P ^e   Cano, J ^f   Carrillo Mun A J ^g   Gene J ^f   Pinel, C ^e   Stevens, D A ^c,h   Sullivan, D J ^d  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e UNIV GRENOBLE ALPES   (France)

^f UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^g Associacio Catalana d'Intelligencia Artificial   (Spain)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candida dubliniensis; Fusarium; Saccharomyces cerevisiae; Scedosporium prolificans

Indexed keywords

ABC TRANSPORTER; ALBACONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTISONE; FLUCONAZOLE; FLUCYTOSINE; FUMONISIN B1; FUMONISIN B2; GLIOTOXIN; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MYCOTOXIN; POSACONAZOLE; RAVUCONAZOLE; RIFAMPICIN; TERBINAFINE; TRIAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; BONE MARROW TRANSPLANTATION; CANDIDA DUBLINIENSIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; ESOPHAGUS CANCER; EXPERIMENTAL MODEL; FUSARIUM; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEUTROPENIA; NONHUMAN; PREVALENCE; SACCHAROMYCES CEREVISIAE; SCEDOSPORIUM; TAXONOMY; THRUSH; VAGINITIS; VIRULENCE; VIRUS MORPHOLOGY;

CANDIDA; FUNGI; FUSARIUM; HUMANS; MYCOSES; OPPORTUNISTIC INFECTIONS; SACCHAROMYCES CEREVISIAE; SCEDOSPORIUM; VIRULENCE;

ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; FILOBASIDIELLA NEOFORMANS; FUNGI; FUSARIUM; HUMAN IMMUNODEFICIENCY VIRUS; SACCHAROMYCES CEREVISIAE; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS;

EID: 0034507618     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.38.s1.225.236     Document Type: Article

References (127)

1. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Surveillance System
2. The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992-1993: Results of population-based laboratory active surveillance
3. New and emerging yeast pathogens
4. The new fungal opportunists are coming
5. Emerging disease issues and fungal pathogens associated with HIV infection
6. Fungal infection rates are increasing
7. Endemic mycoses in AIDS: A clinical review
8. Bread-making as a source of vaginal infection with Saccharomyces cerevisiae: Report of a case in a woman and apparent transmission to her partner
9. Saccharomyces cerevisiae pneumonia in a patient with acquired immune deficiency syndrome
10. Vaginitis due to Saccharomyces cerevisiae: Epidemiology, clinical aspects, and therapy
11. Saccharomyces cerevisiae vaginitis: Transmission from yeast used in baking
12. Fungemia with Saccharomycetaceae
13. Epidemiological investigation of vaginal Saccharomyces cerevisiae isolates by a genotypic method
14. Saccharomyces cerevisiae fungemia: Case report and review of the literature
15. Invasive infection with Saccharomyces cerevisiae: Report of three cases and review
16. Genetic characterization of pathogenic Saccharomyces cerevisiae isolates
17. Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae
18. Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice
19. Application of DNA typing methods and genetic analysis to epidemiology and taxonomy of Saccharomyces
20. Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42°C and form pseudohyphae
21. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.)
22. Intergenic transcribed spacer PCR ribotyping for differentiation of Saccharomyces species and interspecific hybrids
23. Colony phenotype switching in clinical and non-clinical isolates of Saccharomyces cerevisiae
24. Comparative virulence of petite and grand isolates of Saccharomyces cerevisiae (Sc)
25. Correlation of petite formation frequency by isolates of Saccharomyces cerevisiae (SC) in vitro with virulence
26. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates
27. Molecular and epidemiological characterization of vaginal Saccharomyces cerevisiae isolates
28. Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile-induced colonic secretion in the rat
29. Impact of the changing epidemiology of fungal infections in the 1990s
30. Opportunistic candidiasis: An epidemic of the 1980s
31. Epidemiology of nosocomial fungal infections
32. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission
33. Oral Candida in HIV infection and AIDS: New perspectives/new approaches
34. Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species
35. From bamboo rats to humans: The odyssey of Penicillium marneffei
36. Candida dubliniensis sp. nov.: Phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals
37. Candidiasis: The emergence of a novel species, Candida dubliniensis
38. Molecular and phenotypic analysis of Candida dubliniensis: A recently identified species linked with oral candidosis in HIV-infected and AIDS patients
39. Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals
40. Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting
41. Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients
42. Cluster of oral atypical Candida isolates in a group of human immunodeficiency virus-positive drug users
43. Characterization of genetically distinct subgroup of Candida albicans strains isolated from oral cavities of patients infected with human immunodeficiency virus
44. A novel group I intron in Candida dubliniensis is homologous to a Candida albicans intron
45. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5′ end of the large-subunit (26S) ribosomal DNA gene
46. Candida dubliniensis: Phylogeny and putative virulence factors
47. Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences
48. Rapid identification of Candida dubliniensis with commercial yeast identification systems
49. Identification of Candida dubliniensis based on temperature and utilization of xylose and α-methyl-D-glucoside as determined with the API 20C AUX and Vitek YBC systems
50. Use of specialised isolation media for recognition and identification of Candida dubliniensis isolates from HIV-infected patients
51. Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes
52. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates
53. Prevalence of Candida dubliniensis isolates in a yeast stock collection
54. Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans
55. Distinctive carbohydrate assimilation profiles used to identify the first clinical isolates of Candida dubliniensis recovered from the United States
56. Candida dubliniensis: Characteristics and identification
57. Identification of Candida dubliniensis in a prospective study of patients in the United States
58. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
59. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation
60. Candida dubliniensis fungemia: The first four cases in North America
61. Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel
62. Isolation of C. dubliniensis from insulin-using diabetes mellitus patients
63. Initial case of Candida dubliniensis infection from Asia: Non-mucosal infection
64. New PCR primer pairs specific for Candida dubliniensis and detection of the fungi from the Candida albicans clinical isolates in Japan
65. Candida dubliniensis: An update
66. Adherence of clinical Candida dubliniensis isolates in the presence of fluconazole
67. Difference in virulence of Candida dubliniensis strains in mice and comparison to C. albicans
68. First report of Candida dubliniensis in Brazilian AIDS patients
69. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro
70. Development and characterization of complex DNA fingerprinting probes for the infectious yeast Candida dubliniensis
71. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis
72. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
73. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
74. Fusarium solani infection during treatment for acute leukemia
75. Fusarium, a newly recognized fungal pathogen in immunosuppressed patients
76. Clinical patterns of Fusarium infections in immunocompromised patients
77. Fusarium infections in immunocompromised patients: Case reports and literature review
78. Opportunistic fusarial infections in humans
79. Infections à Fusarium
80. Invasive mold infections in cancer patients: 5 years experience with Aspergillus, Mucor, Fusarium and Acremonium infections
81. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years experience at a cancer center and implication for management
82. Invasive Fusarium infections: A retrospective survey of 31 cases
83. Primary pulmonary involvement of Fusarium solani in a lung transplant recipient
84. Experimental fusarial hyalohyphomycosis in a murine model
85. Fungal keratitis due to Fusarium and other fungi
86. Ecological distribution of Fusarium solani and its opportunistic action related to mycotic keratitis in Cali, Colombia
87. Les champignons du milieu extérieur responsables d'allergies
88. Evaluation of an environmental control strategy for prevention of nosocomial invasive aspergillosis
89. Water as a source of filamentous fungi in a childhood bone marrow transplantation unit
90. Mycotoxines
91. Fumosinin BI, a mycotoxin contaminant of cereal grains and inducer of apoptosis via the tumour necrosis factor pathway and caspase activation
92. Case study of bovine dermatitis caused by oat straw infected with Fusarium sporotrichoides
93. Analysis of Fusarium causing dermal toxicosis in marran grass planters
94. In vivo suppressive activity of gliotoxin, a metabolite produced by human pathogenic fungi
95. Invasion and survival of Fusarium solani in the dexamethasone-treated cornea of rabbits
96. Catheter-associated fungemia caused by Fusarium chlamydosporum in a patient with lymphocytic lymphoma
97. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani
98. Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for Amphotericin B against Fusarium
99. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species
100. In vitro sensitivity of medically significant Fusarium species to various antimycotics
101. Therapy of deep fungal infection in haematological malignancy
102. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation
103. Mycoses profondes de l'immunodéprimé et du patient débilité
104. Detection of plasma (1-3)-β-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias
105. Diagnosis of systemic mycoses by specific immunohistochemical tests
106. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology
107. Immunohistologic identification of Aspergillus spp. and other hyaline fungi by using polyclonal flourescent antibodies
108. Specific detection of Fusarium species in blood and tissues by a PCR technique
109. Moulds with enteroblastic conidia adhering in wet masses
110. Fusarium infections. Criteria for the identification of the responsible species
111. Relationships of Scedosporium prolificans with Petriella confirmed by partial LSU rDNA sequences
112. Relatedness of Pseudallescheria, Scedosporium and Graphium pro parte based on SSU rDNA sequences
113. Clinical pathologic and epidemiologic features of infection with Scedosporium prolificans: Four cases and review
114. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of literature
115. Acremonium species: New emerging fungal opportunists - In vitro antifungal susceptibilities and review
116. Clinical features of human infection with Scedosporium inflatum
117. Clinical resolution of Scedosporium prolificans pneumonia associated with treatment with liposomal amphotericin B in a patient with acute leukemia
118. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenic following administration of granulocyte colony-stimulating factor
119. Lomentospora prolificans, a new hyphomycete from greenhouse soil
120. Potted plants in hospitals as reservoirs of pathogenic fungi
121. Incremento de las infecciones por Scedosporium prolificans en un hospital general
122. Transmisión aérea de Scedosporium prolificans en la infección nosocomial
123. Experimental infection with Scedosporium inflation